NCT03450187View on ClinicalTrials.gov

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

March 31, 2019

Conditions
Bacterial Infections
Interventions
DRUG

TP-271

multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.

Trial Locations (1)

78744

PPD Phase I Clinic, Austin

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Tetraphase Pharmaceuticals, Inc

INDUSTRY

NCT03450187 - A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study | Biotech Hunter | Biotech Hunter